POPULARITY
Categories
369 episodes with CMC
278 episodes with CMC
180 episodes with CMC
68 episodes with CMC
115 episodes with CMC
57 episodes with CMC
39 episodes with CMC
88 episodes with CMC
33 episodes with CMC
47 episodes with CMC
109 episodes with CMC
34 episodes with CMC
36 episodes with CMC
29 episodes with CMC
22 episodes with CMC
41 episodes with CMC
24 episodes with CMC
81 episodes with CMC
28 episodes with CMC
10 episodes with CMC
83 episodes with CMC
20 episodes with CMC
16 episodes with CMC
20 episodes with CMC
28 episodes with CMC
20 episodes with CMC
54 episodes with CMC
8 episodes with CMC
14 episodes with CMC
18 episodes with CMC
14 episodes with CMC
18 episodes with CMC
14 episodes with CMC
18 episodes with CMC
9 episodes with CMC
8 episodes with CMC
9 episodes with CMC
8 episodes with CMC
21 episodes with CMC
8 episodes with CMC
15 episodes with CMC
10 episodes with CMC
10 episodes with CMC
4 episodes with CMC
8 episodes with CMC
7 episodes with CMC
12 episodes with CMC
7 episodes with CMC
10 episodes with CMC
9 episodes with CMC
8 episodes with CMC
18 episodes with CMC
7 episodes with CMC
36 episodes with CMC
4 episodes with CMC
8 episodes with CMC
10 episodes with CMC
7 episodes with CMC
15 episodes with CMC
7 episodes with CMC
5 episodes with CMC
6 episodes with CMC
7 episodes with CMC
9 episodes with CMC
6 episodes with CMC
7 episodes with CMC
5 episodes with CMC
4 episodes with CMC
7 episodes with CMC
7 episodes with CMC
17 episodes with CMC
5 episodes with CMC
7 episodes with CMC
7 episodes with CMC
4 episodes with CMC
5 episodes with CMC
7 episodes with CMC
5 episodes with CMC
4 episodes with CMC
9 episodes with CMC
3 episodes with CMC
4 episodes with CMC
6 episodes with CMC
6 episodes with CMC
5 episodes with CMC
7 episodes with CMC
3 episodes with CMC
8 episodes with CMC
9 episodes with CMC
4 episodes with CMC
5 episodes with CMC
7 episodes with CMC
5 episodes with CMC
16 episodes with CMC
4 episodes with CMC
5 episodes with CMC
8 episodes with CMC
3 episodes with CMC
5 episodes with CMC
6 episodes with CMC
5 episodes with CMC
4 episodes with CMC
4 episodes with CMC
6 episodes with CMC
11 episodes with CMC
9 episodes with CMC
9 episodes with CMC
5 episodes with CMC
4 episodes with CMC
5 episodes with CMC
5 episodes with CMC
5 episodes with CMC
3 episodes with CMC
8 episodes with CMC
11 episodes with CMC
4 episodes with CMC
4 episodes with CMC
6 episodes with CMC
12 episodes with CMC
2 episodes with CMC
10 episodes with CMC
4 episodes with CMC
4 episodes with CMC
4 episodes with CMC
3 episodes with CMC
3 episodes with CMC
3 episodes with CMC
5 episodes with CMC
3 episodes with CMC
4 episodes with CMC
14 episodes with CMC
4 episodes with CMC
7 episodes with CMC
71 episodes with CMC
4 episodes with CMC
5 episodes with CMC
3 episodes with CMC
4 episodes with CMC
2 episodes with CMC
4 episodes with CMC
3 episodes with CMC
3 episodes with CMC
5 episodes with CMC
5 episodes with CMC
4 episodes with CMC
67 episodes with CMC
4 episodes with CMC
4 episodes with CMC
4 episodes with CMC
3 episodes with CMC
2 episodes with CMC
3 episodes with CMC
2 episodes with CMC
2 episodes with CMC
2 episodes with CMC
7 episodes with CMC
2 episodes with CMC
3 episodes with CMC
5 episodes with CMC
3 episodes with CMC
3 episodes with CMC
3 episodes with CMC
Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.Highlights from the episode:When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. Sonal's 17th Season starts up and Episode 6 features a Newsworthy update on the OIG Work Plan for February 2026.Sonal's Trusty Tip and compliance recommendations focus on a new moratorium issued to DMEPOS medical suppliers.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Aaron Rose.Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.Highlights from the episode:Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
How solid is your CMC foundation—and what happens if it cracks under pressure?David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.His “house building” approach demystifies CMC's complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.Tune in to hear Henri's practical wisdom distilled through real-world analogies:Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)Process validation explained: FDA's three stages, from control strategy justification to continued verification (05:15)Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)Smart insight:Never underestimate CMC. If you do, you will pay for it later.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
A defesa dos San Francisco 49ers precisa evoluir em 2026 para voltar a ser dominante como nos anos recentes — especialmente no pass rush (última temporada foi fraca em sacks e pressão) e no interior da linha defensiva. Neste episódio, exploramos não só o que precisa mudar, mas como a franquia pode usar a free agency estrategicamente para reforçar o front seven. Como pontos centrais: O pass rush sofreu sem produção consistente no ano anterior e a equipe vai atrás de edge rushers com impacto imediato; No interior da linha, com defensores como Kevin Givens, Jordan Elliott e Kalia Davis entrando na free agency, há espaço para adicionar veteranos. Além disso, reforçar a secundária e a cobertura foi tema de análise. Desenvolver um plano defensivo sólido passa por reter talentos internos e buscar peças que preencham lacunas de produção. No episódio, discutimos projeções de free agents, cap space e como equilibrar adições com crescimento de jovens talentos para criar uma defesa completa em 2026. ⭐ Deixe sua nota no spotify e compartilhe o episódio com outros torcedores Faithful! ✅ Curte o conteúdo? Deixa o like, se inscreve no canal do YouTube, se inscreve no podcast e ativa o sininho pra acompanhar tudo sobre os Niners!
Send a textDr. Sharron Gargosky, Ph.D. is Chief Clinical Officer of Spinogenix, Inc. ( https://spinogenix.com/ ), a clinical-stage company pioneering a new class of therapeutics designed to reverse synaptic loss and dysfunction in the brain.Spinogenix is advancing two first-in-class oral small molecules. Tazbentetol is a synaptic regenerative therapy shown to regrow brain synapses — the vital connections between neurons. Clinical data have demonstrated rapid and significant improvements in memory and thinking in Alzheimer's disease, as well as clinically meaningful slowing of disease progression in ALS. The therapy is also being evaluated in schizophrenia, with a Phase 2 trial underway. Tazbentetol has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for ALS, and the company has established an Expanded Access Program to provide investigational treatment options to eligible ALS patients.Spinogenix's second program, SPG601, is a synaptic corrective therapy for Fragile X Syndrome — the leading inherited cause of intellectual disability and a known genetic driver of autism. Clinical data have shown normalization of abnormal brain activity patterns and improvements in attention and focus. SPG601 has received Orphan Drug and Fast Track Designations and is advancing toward late-stage development.Dr. Gargosky brings more than 25 years of global development leadership experience across small molecules, biologics, cell therapies, and diagnostics. She has overseen regulatory, CMC, non-clinical, clinical, and medical affairs programs across more than 15 countries, and has led multiple orphan and accelerated approval pathways.Previously, Dr. Gargosky held senior leadership roles at OncoSec Medical, Prima Biomed, Hyperion Therapeutics, Pfizer, and served in academia at Stanford University and Oregon Health & Science University.#Spinogenix #SynapticRegeneration #FragileX #AlzheimersResearch #ALSResearch #Neuroscience #BrainHealth #BiotechInnovation #Synaptopathy #ClinicalTrials #RegenerativeMedicine #Neurodevelopment #SharronGargoskySupport the show
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. Sonal's 17th Season starts up and Episode 5 features a return to her spotlight series on Newsworthy interviews that are also filled with Trusty Tips. Join Sonal on welcoming back a fan favorite! Let's hear all about what's been going on in the life and times of Keisha Wilson.Find Keisha on LinkedIn:https://www.linkedin.com/in/keisha-wilson-ccs-cpc-cpco-crc-cpb-cpma-approved-instructor-1894b762/Get a copy of Keisha's new book, By Her Side:https://byhersidefaithfulcaregiver.com/?mc_cid=73567e3451&mc_eid=b4ee9275f2Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Code MATTEK on DraftKings: https://dkdfs.sng.link/Avkw3/begf?_dl=draftkings%3A%2F%2Fgateway%3Fs%3D783701309&pcid=428729&psn=3171&pcn=EarlyBirdBestBall&pscn=QRCode&pcrn=xx&pscid=xx&pcrid=xx&wpcid=428729&wpsrc=3171&wpcn=EarlyBirdBestBall&wpscn=QRCode&wpcrn=xx&wpscid=xx&wpcrid=xx&_forward_params=1
A new study, Women in the Workplace 2025, reports a troubling reversal: stalled early advancement, declining company commitment, and a new ambition gap as fewer women aspire to promotion than men for the first time in a decade. In a fast growing Central Ohio economy, this Columbus Metropolitan Club forum asks: are women being left behind just as opportunity expands? New research from McKinsey & Company and LeanIn.org shows that only 80% of women now aspire to promotion, compared with 86% of men—a reversal of long-standing trends. Yet the data tells a more hopeful story as well: when women receive the same sponsorship, support, and clarity about advancement as their male peers, the ambition gap disappears entirely. The problem, it turns out, may not be women's ambition—but workplaces that make ambition harder to sustain. Leaders from business and the nonprofit sector discuss what is driving the ambition gap, why it disappears when women receive equal sponsorship and support, and what leaders can do to build workplaces where women can advance. Featuring: Michelle Bryant, Partner, McKinsey and Company Dr. Pamela Gregory, Owner and CFO, National Center for Urban Solutions Kelley Griesmer, President and CEO, The Women's Fund of Central Ohio Lillian Morales Laster, Executive Director, Empowering Latinas Leadership Academy The host is Margaret D Finley, President, Central Ohio Belonging Consortium. This forum was made possible by the Mary Lazarus Legacy in Civic Engagement Fund and was sponsored by Advanced Drainage Systems, Event Marketing Strategies, and The New Directions Career Center. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. CMC's livestream partner was The Columbus Dispatch. If you'd like to keep exploring this week's forum topic, our friends at The Columbus Metropolitan Library recommend reading This Isn't Working: How Working Women Can Overcome Stress, Guilt, and Overload to Find True Success by Meghan French Dunbar (2025). This forum was recorded before a live audience at The National Veterans Memorial and Museum in Columbus Ohio on March 4, 2026.
Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.What you will learn:Evolution of cell bank technology and regulatory expectations (00:33)The impact of weak CMC foundations on late-stage failure (00:51)Lessons learned from Ferring's gene therapy approval and CMC gap analysis (06:51)FDA statistics on CMC issues in INDs and response letters (08:07)Critical early decisions: cell bank clonality and proper storage practices (10:22)The importance of comprehensive raw material documentation (12:29)Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)Supply strategy for phase 2—why stability and batch knowledge matter (14:49)Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)Common pitfalls in CQA identification and continued process verification (17:01)Smart insight:The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Everything Life Coaching: The Positive Psychology and Science Behind Coaching
In this conversation on The Everything Life Coaching Podcast, Noelle Cordeaux, CEO of Lumia, sits down with Juliann Wiese, B.Ed., CPCC, MCC, CMC and Karyn Edwards, PhD, MCC... both longtime Lumia instructors and corporate leadership veterans who've collectively spent decades inside organizations before hanging up their shingles and building thriving independent practices. They get into the real talk of what it means to move from doing coaching to being a coach, letting go of ego, performance, and the constant toggling of skills, and what it looks like when the work finally becomes embodied. Juliann and Karyn also unpack what just changed in the ICF core competencies (updated November 2025) and why the renewed emphasis on mentorship and self-awareness as a coach is the future of the profession. These two are launching a mentor coaching cohort together, designed for coaches working in or aspiring to corporate environments, led by two of the roughly 4-5% of ICF-credentialed coaches worldwide who hold the MCC designation. They break down what questions you should actually be asking before choosing a mentor coach, why development beats checkbox-chasing every time, and what makes this program different. Only 10 spots. Cohort starts April 2nd, 2026. If you're sitting on your PCC or ACC and wondering what's next... sign up for the Mentor Coaching Cohort: https://www.surveymonkey.com/r/Mentor_Coach Everything Life Coaching is brought to you by Lumia. At Lumia, we train and certify impact-driven coaches, making sure they've got all they need to build a career they love and transform lives, on their terms. Become a life coach, and make a bigger impact on the world around you! Schedule a call with us today to discuss your future as a coach. Contact Karyn Edwards Contact Juliann Wiese Music in this episode is by Cody Martin, used under a creative commons license. The Everything Life Coaching Podcast is Produced and Audio Engineered by Amanda Meyncke.
What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.Topics covered:The strategic advantage of B2B commercialization in consumer care biotech (02:46)Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)Building a pilot facility and moving toward technology licensing for global reach (05:33)Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)Strategic insight:Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.Explore the full story and hear Tim's advice for both founders and innovators.If you're interested in other unconventional biological platforms reshaping biomanufacturing, don't miss:Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorConnect with Tim Corcoran:LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/Deep Blue Biotech: www.deepbluebiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, BA, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 years on Feedspot.Sonal's 17th Season starts up and Episode 4 features Newsworthy updates on the month's fraud, waste, and abuse cases. Sonal's Trusty Tip and compliance recommendations focus on surgical dressings.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Vincent Van Gogh.Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Hair is never just hair—it's history, artistry, and identity woven together. Inspired by the upcoming production of Jaja's African Hair Braiding (at the Contemporary Theatre of Ohio, March 5–22, 2026), this forum invites you into a conversation about the cultural, economic, and social significance of African hair braiding and the stories braided into every strand. Jaja's African Hair Braiding, written by Ohio State University graduate Jocelyn Bioh, follows West African women building lives inside a Harlem salon. African hair braiding is more than a beauty practice; it is a tradition deeply rooted in Black communities, symbolizing heritage, creativity, and belonging. In Columbus, braiding salons—often owned and operated by Black women—are more than businesses. They're spaces of empowerment, entrepreneurship, and cultural exchange, where clients and stylists alike find connection and community. Community leaders, artists, scholars, and business advocates discuss how beauty culture reflects resilience, creativity, and economic opportunity—and why these community spaces matter now more than ever. Featuring panelists: Juanita Brent, Representative, Ohio State House District 18 Sarai Brooks, Braid Artist, Author, and Owner of Haven 626 by RaiStyles J. Averi Frost, Executive Director, Central Ohio African American Chamber of Commerce Dr. Treva B. Lindsey, Professor of Women's, Gender, and Sexuality Studies, The Ohio State University The host is Lachandra "La" Baker, Founder and Lead Consultant, Lachandra B. Baker Edutainment LLC. This forum was presented in partnership with The Contemporary Theatre of Ohio. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. CMC's livestream partner was The Columbus Dispatch. This forum was also supported by Downtown Columbus Inc and The National Veterans Memorial and Museum. If you would like to keep exploring this week's forum topic, our partners at The Columbus Metropolitan Library recommend reading "Twisted: The Tangled History of Black Hair Culture," by Emma Dabiri (2020). This forum was recorded before a live audience at The National Veterans Memorial and Museum in Columbus, Ohio on February 25, 2026.
Damon Bruce Plus: Warriors, 49ers, Giants, A’s Bay Area Sports Talk
CMC can't be an "army of one" in 2026. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
Women's health is at a pivotal moment in Ohio. From maternal care deserts and rising maternal mortality, to oncology advances and long-overdue conversations about menopause and postpartum mental health, this Columbus Metropolitan Club forum explores what our region is getting right—and where the system is still failing Ohio's women. Featuring Panelists: Jatu Boikai, Founder and CEO, Central Ohio Postpartum Extended Respite Center Dr. Kamilah Dixon, Director of the General Division of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center Dr. Shilpa Padia, Co-Medical Director of Oncology, Mount Carmel Health System Dr. Mona Prasad, System Chief, Maternal Fetal Medicine, OhioHealth Physicians Group Your host is Tracy Townsend, News Anchor and Medical Correspondent, WBNS 10TV. The presenting sponsors of CMC's long-running Optimal Health Series are Nationwide Children's Hospital, OhioHealth, and The Ohio State University Wexner Medical Center. This forum was also sponsored by Mount Carmel Health System. The presenting sponsor of the CMC livestream is The Center for Human Kindness at the Columbus Foundation. CMC's livestream partner is The Columbus Dispatch. This forum was also supported by Downtown Columbus, Inc. and The National Veterans Memorial and Museum. If you would like to keep exploring this week's forum topic, our partners at The Columbus Metropolitan Library recommend reading "The New Rules of Women's Health: Your Guide to Thriving at Any Age" by Meghan Rabbitt (2026). This forum was recorded before a live audience at the National Veterans Memorial and Museum in Columbus, Ohio on Wednesday, February 18, 2026.
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. Sonal's 17th Season starts up and Episode 3 features a return to her spotlight series on Newsworthy interviews that are also filled with Trusty Tips. Join Sonal on welcoming Robyn Alvarado and hear her talk about her Journey.Find Robyn on LinkedIn:https://www.linkedin.com/in/robyn-marie-alvarado-cpc-cpma-12507a22/Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
In this Complex Care Journal Club podcast episode, Drs. Kathleen Chiotos and Jeffrey Gerber discuss a post hoc time-series analysis of clinician feedback reports and antibiotic prescribing for community-acquired pneumonia in children with medical complexity (CMC). They describe why children with medical complexity are often excluded from guideline-based interventions, what the data suggest about antibiotic choice and duration in this population, and next steps to design studies that include all children. SPEAKERS Kathleen Chiotos, MD, MSCE Associate Professor of Anesthesiology and Critical Care University of Pennsylvania, Children's Hospital of Philadelphia Jeffery Gerber, MD, PhD Professor of Pediatrics and Epidemiology University of Pennsylvania School of Medicine; Children's Hospital of Philadelphia HOST Kristina Malik, MD Assistant Professor of Pediatrics, University of Colorado School of Medicine Medical Director, KidStreet Pediatrician, Special Care Clinic, Children's Hospital Colorado DATE Initial publication date: February 17, 2026. JOURNAL CLUB ARTICLE Chiotos K, Dutcher L, Grundmeier RW, Szymczak JE, Lautenbach E, Neuhauser MM, Hicks LA, Hamilton KW, Li Y, Muller BM, Meyahnwi D, Congdon M, Kane E, Hart J, Utidjian L, Cressman L, Jaskowiak-Barr A, Gerber JS. Off-target Impact of Clinician Feedback Reports on Antibiotic Use in Children With Medical Complexity Hospitalized With Community-Acquired Pneumonia. J Pediatric Infect Dis Soc. 2025 Oct 2;14(10):piaf089. doi: 10.1093/jpids/piaf089. PMID: 41051365. OTHER ARTICLES REFERENCED Chiotos K, Dutcher L, Grundmeier RW, Meyahnwi D, Lautenbach E, Neuhauser MM, Hicks LA, Hamilton KW, Li Y, Szymczak JE, Muller BM, Congdon M, Kane E, Hart J, Utidjian L, Cressman L, Jaskowiak-Barr A, Gerber JS. Impact of Clinician Feedback Reports on Antibiotic Use in Children Hospitalized With Community-acquired Pneumonia. Clin Infect Dis. 2025 Feb 24;80(2):263-270. doi: 10.1093/cid/ciae593. PMID: 39656188; PMCID: PMC12120840. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014 Aug 8;14:199. doi: 10.1186/1471-2431-14-199. PMID: 25102958; PMCID: PMC4134331. TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/bgxn4mqgk45zjxhxpxgxf3px/Chiotos_and_Gerber_podcast_2-13-26 Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6. Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Chiotos K, Gerber JS, Malik K. Evidence for Everyone: Studying Antibiotic Use for Pneumonia in Children With Medical Complexity. 2/2026. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/evidence-for-everyone-studying-antibiotic-use-for-pneumonia-in-children-with-medical-complexity.
How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribution as a process parameter from the beginning of cell line and media development rather than as a remediation strategy.David Brühlmann outlines the experimental protocol for validating raffinose supplementation, including decision criteria for proceeding or terminating at each development stage. The discussion addresses process design space requirements, analytical monitoring strategy, and the experimental variables that determine when media-based glycan tuning is appropriate versus when alternative approaches are needed.Highlights from the episode:When to use (and not use) raffinose in your development program, including limitations and effectiveness windows (00:30)Essential protocol: three experiments over eight weeks to validate raffinose for your process, with clear go/no-go criteria (04:09)Why individualized mannose tracking (Man5, Man6, Man7, Man8) is crucial for meaningful results (01:06)Managing osmolality: why it matters and how to control it in your experiment (04:36)Advice on scaling up: moving from small-scale screens to benchtop bioreactors and stress-testing your process (07:48)Three key mistakes to avoid when implementing raffinose, including lessons from analytical oversight, incomplete design mapping, and feed interference (09:08)Integrating glycosylation as a core part of process design, not just a secondary consideration after titer optimization (13:10)Strategic insight:Sequential optimization of productivity followed by glycosylation introduces development risk: quality attribute deviations discovered after process lockdown require costly re-optimization cycles. Parallel development of titer and glycan specifications from initial cell line characterization reduces this risk by establishing feasible operating windows early in the development timeline.Are you planning your next recombinant protein scale-up? Hear how David's rule-of-three protocol and battle-tested lessons can help you optimize faster and avoid painful late-stage surprises.Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
a16z general partner Jorge Conde talks with Vasant Narasimhan, CEO of Novartis International, about transforming a 250-year-old conglomerate into a pure play medicines company and unlocking $180 billion of value in the process. They cover Novartis's platform technologies: cell and gene therapies, RNA medicines, and radioligand therapies. They also discuss AI in drug discovery, the rise of China as a biotech competitor, and what Vasant looks for when evaluating startup partnerships, including his advice on the killer experiments and CMC work that can make or break a deal. Resources: Follow Vasant Narasimhan on X: https://twitter.com/VasNarasimhanFollow Jorge Conde on X: https://x.com/JorgeCondeBio Stay Updated:Find a16z on YouTube: YouTubeFind a16z on XFind a16z on LinkedInListen to the a16z Show on SpotifyListen to the a16z Show on Apple PodcastsFollow our host: https://twitter.com/eriktorenberg Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Today, we examine a year that looked chaotic but felt familiar to trend followers. Gold surged, equities rotated globally, and non-US markets quietly gained momentum. Yet beneath strong returns lies a deeper debate about model design, short versus long horizon signals, and whether innovation in liquid alternatives serves investors or sales desks. From AI disruption to product engineering and allocator behavior, this episode explores where systematic strategies truly create value and where structural incentives distort outcomes. In a changing macro regime, clarity of purpose may matter more than ever.-----50 YEARS OF TREND FOLLOWING BOOK AND BEHIND-THE-SCENES VIDEO FOR ACCREDITED INVESTORS - CLICK HERE-----Follow Niels on Twitter, LinkedIn, YouTube or via the TTU website.IT's TRUE ? – most CIO's read 50+ books each year – get your FREE copy of the Ultimate Guide to the Best Investment Books ever written here.And you can get a free copy of my latest book “Ten Reasons to Add Trend Following to Your Portfolio” here.Learn more about the Trend Barometer here.Send your questions to info@toptradersunplugged.comAnd please share this episode with a like-minded friend and leave an honest Rating & Review on iTunes or Spotify so more people can discover the podcast.Follow Andrew on Twitter.Episode TimeStamps: 00:00 - Introducing the Systematic Investor series01:17 - AI disruption and systematic investing06:52 - The shifting perception of US risk09:21 - Winter Olympics and market metaphors12:59 - Hedge funds versus private equity19:23 - 2025 review and the importance of risk allocation22:17 - Why CTAs did not fully capture gold29:48 - Short term versus long term trend models35:27 - Letting risk run versus investor palatability44:43 - The problem with liquid alternatives51:21 - Product design versus fiduciary duty59:06 - QIS, innovation and investor sophistication01:04:41 - Model risk and the myth of risk premia01:10:51 - Hopes for a trending year aheadCopyright © 2025 – CMC
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 Years on Feedspot. Sonal's 17th Season starts up and Episode 2 features a Newsworthy update on the OIG Work Plan for January 2026.Sonal's Trusty Tip and compliance recommendations focus on the new industry segment-specific compliance guidance document issued by the OIG for Medicare Advantage parties.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Elisabeth Kübler Ross.Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Recorded: February 09, 2026 Welcome to another episode of Bussin' With The Boys featuring special guest, 49ers star running back and NFL comeback player of the year, Christian McCaffrey. Will Compton & Taylor Lewan sit down with christian McCaffrey fresh off his Comeback Player of the Year season and carrying the load for a beat-up 49ers roster, CMC gets real about the responsibility of being the guy, the mental side of the grind, and how this season tested him. The conversation also touches on Mac Jones’ strong year, George Kittle battling injuries, and some legendary behind the scenes football talk including stories about Julius Peppers’ freak athleticism and why Luke Kuechly was the gold standard on the practice field in Carolina, when CMC was at the Panthers. Outside the game, CMC talks through how he decompresses, what his daily training routine actually looks like in season, stepping into fatherhood, and how growing up playing multiple sports helped build his skill set. Plus, there’s a classic Super Bowl week moment thrown in that perfectly sums up the chaos of the week. If you’re about top-tier RB play, behind-the-scenes Super Bowl stories, and real locker room football conversations, this one’s for you. 0:00 Intro4:18 KNF Clean Take6:03 Super Bowl Recap8:12 Will Finally Got His House Setup11:01 Taylor Hit Vegas17:46 How Would You Change Super Bowl Week26:05 Guest Rolodex Coming Up31:33 Gooner Of The Month34:40 CHRISTIAN MCCAFFREY INTERVIEW STARTS34:48 CMC Came Through For The Boys36:08 Winning Comeback Player Of The Year40:14 Did He Think About His Mortality?45:01 Him Being “The Guy” This Season & The 49ers Injuries50:24 Dynamic With Mac Jones Balling Out51:25 George Kittle Getting Hurt56:16 What's The Deal Will With The Electrical Substation?1:10:20 How Does CMC Relieve Stress?1:13:36 Training Day In The Life Of CMC1:17:30 Julius Peppers Is A Freak1:19:29 Luke Kuechly Was More Athletic Than People Think1:21:45 Becoming A Father1:28:45 Growing Up Playing Different Sports1:37:01 Bud Light QuestionSee omnystudio.com/listener for privacy information.
When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.Highlights from the episode:The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)Strategic insight:Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.Listen to this episode of the Smart Biotech Scientist Podcast to learn David's best strategies for rapid, regulatory-friendly glycosylation control.If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
How do you build an organization that can absorb change, learn from failure, and keep patients at the center—even when the science is uncertain? Nelly Viseux shares lessons from over 20 years in biotech and a decade leading cell and gene therapy development.Nelly discusses how she structured a 100-person CMC organization at Regeneron to balance innovation with operational execution, why documenting your assumptions is critical to managing risk, and what it really takes to maintain resilience when you're literally holding patient lives in your hands.A few of Nelly's key takeaways:Resilience is adaptability—build organizations that absorb and anticipate change rather than resist itSeparate innovation from execution with intentional gates for when new approaches are ready to implementDocument your assumptions so you can revisit decisions effectively when circumstances changeFailure is a process problem, not a personal one—root cause analysis should improve systems, not assign blameData is the common language that aligns scientists, regulators, and stakeholdersEveryone is a leader in cell therapy—manufacturing and QC teams hold patient lives in their handsAbout Nelly ViseuxNelly Viseux is Vice President of Cell Therapies Development, Manufacturing, Supply & Quality at Regeneron, leading a 100-person organization supporting autologous cell therapy programs. She has over 20 years of biotechnology experience spanning large pharma (Shire, Biogen, Baxter) and startups, working across cell and gene therapies, biologics, and nanoparticles. Her accomplishments include building a Phase 1 cell therapy manufacturing facility that achieved 100% cGMP success and first IND submission within two years. She holds a Ph.D. in Biochemistry and Molecular Biology from University of Lille and is a member of the Society for Immunotherapy of Cancer and the American Society of Gene & Cell Therapy.About The FDA GroupThe FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle—from clinical development to commercialization—with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: https://www.thefdagroup.com/
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Dirty Work Hour 3: The Boys bring you another flaming edition of the Sound Soiree featuring: CMC, Tiffany Haddish, & an enraged Knicks fan, & they also sit down with legendary sportscaster Kenny Mayne to talk Super Bowl.See omnystudio.com/listener for privacy information.
Send us a textSteven & Derek discuss the latest on Maxx Crosby's future with the Raiders, react to the NFL Honors, Pro Football Hall of Fame Class of 2026 & preview Super Bowl 60 between the Seahawks & Patriots (00:58)-Lindsey Vonn skiing with a torn ACL (07:23)-Media row in San Francisco (19:45)-Reaction to Jay Glazer saying Maxx Crosby is done with the Raiders & Crosby's comments (48:27)-49ers playing the Rams in Australia next season (54:34)-NFL Honor Awards: Stafford wins MVP by a vote, CMC gets Comeback Player of the year & more (01:14:49)-Hall of Fame Class: Roger Craig finally gets in, along with Drew Brees, Larry Fitzgerald, Adam Vinateri & Luke Kuechly (01:23:55)-Super Bowl 60 Preview (01:35:12)-Jackass of the Week (01:47:01)-Pop Culture Catch-Up (01:52:34)-Moments of Zen: Gruden sees Gannon in the streets of SF Support the show
Dirty Work Hour 3: The Boys bring you another flaming edition of the Sound Soiree featuring: CMC, Tiffany Haddish, & an enraged Knicks fan, & they also sit down with legendary sportscaster Kenny Mayne to talk Super Bowl.See omnystudio.com/listener for privacy information.
Damon Bruce Plus: Warriors, 49ers, Giants, A’s Bay Area Sports Talk
2:55: No one on Media Row actually seems to be talking about the Super Bowl 10:12: The death of journalism is the plan: 16:11: Jeffery Simmons joins the show: 34:01: Ike joins the show: 37:41: Ed McCaffrey 58:53: Today in history: Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Hour 1: Papa & Silver discuss Roger Craig making the Hall of Fame, and touch on CMC winning the comeback player of the year award. Chris Berman joins the show to share his favorite Super Bowl moments. Matt Maiocco joins the show to discuss why Roger Craig deserves to be in the Hall of Fame and why he finally got the nod. See omnystudio.com/listener for privacy information.
Dirty Work Hour 1: Legendary broadcaster, Kevin Harlan joins the boys to break down the Super Bowl, the Warriors huge win over the Suns, & the crew also break down NFL Awards Night & 49ers running backs getting snubbed & honored (Roger Craig, CMC, Frank Gore)See omnystudio.com/listener for privacy information.
Dirty Work Hour 1: Legendary broadcaster, Kevin Harlan joins the boys to break down the Super Bowl, the Warriors huge win over the Suns, & the crew also break down NFL Awards Night & 49ers running backs getting snubbed & honored (Roger Craig, CMC, Frank Gore)See omnystudio.com/listener for privacy information.
Hour 1: Papa & Silver discuss Roger Craig making the Hall of Fame, and touch on CMC winning the comeback player of the year award. Chris Berman joins the show to share his favorite Super Bowl moments. Matt Maiocco joins the show to discuss why Roger Craig deserves to be in the Hall of Fame and why he finally got the nod. See omnystudio.com/listener for privacy information.
Star running back Christian McCaffrey joined "49ers Talk" host Matt Maiocco on Day 3 of Super Bowl Radio Row at Moscone Center to share his pride in receiving the NFL's 15th annual Salute to Service Award and offer his support to Hall of Fame candidate Roger Craig. Next up was another 49ers legend, Terrell Owens, who stopped by to relive his iconic Sharpie celebration and offer his critique on the Hall of Fame selection process. San Francisco rookie CJ West popped in to discuss areas he can improve in his sophomore season, and former wily quarterback for the Red and Gold, Jeff Garica, shared how he believes current starter Brock Purdy's "underdog" mentality keeps him competitive. Finally, former defensive back Logan Ryan details what traits Upton Stout possesses to be the 49ers' next great nickel corner.--(7:00) CMC honored to receive Salute to Service Award, supports Roger Craig's HOF bid(18:00) Terrell Owens reminisces on iconic Sharpie celebration, discusses Kraft, Belichick HOF snubs(33:00) Where 49ers DT CJ West hopes to improve in his sophomore 49ers season(40:00) Jeff Garcia shares how Brock Purdy's ‘underdog' mentality keeps him competitive(50:00) Former 49ers DB Logan Ryan believes the 49ers found their next great nickel corner in Upton Stout Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Welcome to the Paint The Medical Picture Podcast, created and hosted by Sonal Patel, BA, CPMA, CPC, CMC, ICD-10-CM.Thanks to all of you for making this a Top 15 Medical Billing & Coding Podcast for 5 years on Feedspot.Sonal's 17th Season starts up and Episode 1 features a Newsworthy update on 5 new telehealth services in 2026.Sonal's Trusty Tip and compliance recommendations focus on audit plans for office visits rendered via telehealth.Spark inspires us all to reflect on beauty, abundance, and innovation based on the inspirational words of Kahlil Gibran.Check out Sonal's NAMAS article:https://namas.co/5-steps-to-update-your-audit-plan-for-office-visits-via-telehealth/Paint The Medical Picture Podcast now on:Spotify: https://open.spotify.com/show/6hcJAHHrqNLo9UmKtqRP3XApple Podcasts: https://podcasts.apple.com/us/podcast/paint-the-medical-picture-podcast/id1530442177Amazon Music: https://music.amazon.com/podcasts/bc6146d7-3d30-4b73-ae7f-d77d6046fe6a/paint-the-medical-picture-podcastFind Paint The Medical Picture Podcast on YouTube: https://www.youtube.com/channel/UCzNUxmYdIU_U8I5hP91Kk7AFind Sonal on LinkedIn: https://www.linkedin.com/in/sonapate/And checkout the website: https://paintthemedicalpicturepodcast.com/If you'd like to be a sponsor of the Paint The Medical Picture Podcast series, please contact Sonal directly for pricing: PaintTheMedicalPicturePodcast@gmail.com
Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.In this episode, you'll learn:The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)Strategies for building more predictive, clinically relevant research models (06:09)Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)Strategic insight:Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.Connect with Bryan Miller:LinkedIn: www.linkedin.com/in/bryan-miller-148344aaCrown Bioscience: www.crownbio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Fine, light, textured, yet strong. Donations, Merchandise, Newsletter, more: https://www.podrunner.com Groovelectric: Downloadable Soul https://www.groovelectric.com PLAYLIST 01. Diana May - Distant (Tim Kollberg Remix) 02. Roald Velden - Letting Go 03. Roald Velden - In My Dreams You're Always There 04. Martina Budde X Da Clubbmaster - Everybody Wants to Rule (Extended Mix) 05. Nipika & Haris V. - Staying Strong (Instrumental Mix) 06. Shyro & Anix Jay - Divine Waves (Devin Jay Remix) 07. Rockka & Kryptone (SL) - Resurgent (Morning Mix) 08. Coss Bocanegra - Somos Como Una Flor 09. Gad Ben David - Olympus 10. Deep Sure, Denis Vostru - Hummingbird 11. CMC & Silenta - Gonna Be Alright (Intrumental) 12. Cosmin Fogoros & Alex Modoi - Chasing Cars (Extended Mix) == Please support these artists == Podrunner is a registered trademark of Podrunner LLC. Music copyright © or CC the respective artists. All other material ©2006, 2026 by Podrunner LLC. For personal use only. Any unauthorized reproduction, editing, exhibition, sale, rental, exchange, public performance, or broadcast of this audio is prohibited. No part of Podrunner or its website and associated content may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems.
Covino & Rich broadcast live from Radio Row in San Francisco for Super Bowl 60 in this Best Of edition! The guys are joined by the Panthers QB Bryce Young & Running Back Rico Dowdle to talk all things about locker room dynamics & how the team will be back better than ever next year. 49ers Wide Receiver Kendrick Bourne joins the guys to talk about their one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation + Comedian Frank Caliendo stops by! See omnystudio.com/listener for privacy information.
49ers Wide Receiver Kendrick Bourne joins the guys to talk about the team's one of a kind of comradery in the locker room, how CMC has been such a huge part of that strong team foundation & if he believes there’s some kind of truth behind those practice field conspiracies in San Fran! Comedian Frank Caliendo swings by & goes over the impressions the guys always do on a regular basis! See omnystudio.com/listener for privacy information.
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Following Robert Saleh's hiring as Tennessee Titans head coach, sources confirmed to NBC Sports Bay Area that Raheem Morris will sign on as San Francisco's fifth defensive coordinator in the last five seasons. Also, in another top organizational move, Jed York announced Monday the promotion of Al Guido to the role of CEO. On this episode of "49ers Talk," Matt Maiocco sits down with Guido to discuss his promotion, his hard work in bringing Super Bowl LX to the Bay Area and how the 49ers' front office and coaching staff's synergy has provided stability that is rare in the NFL these days. They also touch upon the logistics required to host a Super Bowl twice in 10 years, and the possibility of the 49ers playing two international games this coming season. Matt also interviews talkSPORT commentator Will Gavin about his viral call of the "Skyy Bang Reverse Pass" play that was key to San Francisco's fourth-quarter comeback vs. the Eagles in NFC wild-card playoffs.--6:00 - 1-on-1 with newly promoted 49ers CEO Al Guido12:00 Guido's work on bringing Super Bowl LX to Levi's14:00 - Dynamic between the coaching staff and 49ers' front office19:00 - 49ers are in a window next season to play international home game or two20:00 - talkSPORT commentator Will Gavin breaks down viral call of 49ers play23:00 - More people have contacted CMC about the call than the actual play Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Imagine treating cancer with the precision of a guided missile—delivering radioactive payloads directly to tumor cells. Radiopharmaceuticals are reshaping cancer diagnostics and therapy by pairing tumor-targeting molecules with radioisotopes for diagnosis or therapy. But what does it really take to develop these therapies, and why is interest from scientists, biotech companies, and pharma accelerating?In this episode, we're joined by Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK. From a PhD in cardiac disease to leading preclinical oncology and radiopharmaceutical programs, Bryan brings hands-on insight into building advanced cancer models and translating innovative therapies from bench to clinic.Topics discussed include:Bryan Miller's path from cardiac disease research to leading preclinical cancer model development (03:03)Crown Bioscience's comprehensive cancer model platforms, from organoids to PDX and humanized in vivo models (04:05)How radiopharmaceuticals differ from traditional chemotherapies in terms of safety and speed, including the concept of theranostics (07:32)The reasons behind the surge of interest in radiopharmaceuticals within science and industry (09:04)The importance of selecting the right preclinical model for success—and how AI and data-driven approaches will shape future workflows (10:11)Critical pitfalls and unique technical challenges in radiopharmaceutical drug development (12:46)Crown Bioscience's collaborative approach with Medicines Discovery Catapult to navigate the complexities of radiopharmaceutical research (13:35)The diverse client needs, from small startups to global pharma companies, and how mature their development programs can be (14:20)Strategies for scaling preclinical and translational capabilities to meet growing demand in radiopharmaceutical studies (16:04)Strategic insight:Radiopharmaceutical success requires integrated design from the start—combining precise model selection, targeting strategy, isotope choice, linker chemistry, and rigorous QC. Programs that establish this comprehensive foundation early move faster and with higher translational confidence than those addressing these elements sequentially or treating any aspect as a downstream refinement.If you're curious about the real challenges of drug development, the rise of theranostics, and how data-driven approaches (including AI) are shaping preclinical workflows, this episode delivers actionable strategies and insider perspectives for scientists and biotech innovators alike.Connect with Bryan Miller:LinkedIn: www.linkedin.com/in/bryan-miller-148344aaCrown Bioscience: www.crownbio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
Thanks for listening to the podcast! If you are a first-time listener, welcome to the CMC family! Our heart behind this podcast is to serve, so we hope today's content equips and challenges you to be all that God has called you to be! If you would like to know more, please follow us on Instagram, Facebook, and YouTube.
In this episode of Inside Winemaking, Jim Duane speaks with Leigh Meyering of MyEnologist about the practical and analytical aspects of heat and cold stability in wine. The discussion focuses on how and why protein haze and tartrate instability occur, with an emphasis on white and rosé wines. Leigh explains the principles behind heat stability testing, protein denaturation, and the use of bentonite to prevent haze, as well as how stability concerns differ between red wines and lighter-colored styles. The conversation also addresses the sensory and chemical impacts of stabilization decisions, including common concerns around stripping, mouthfeel, and visual clarity in finished wines. The episode then moves into cold stability, detailing the Davis conductivity, DIT, and ISTC 50 tests and how to choose the appropriate method based on a winery's stabilization strategy. Leigh outlines the roles of traditional chilling and seeding, carboxymethyl cellulose (CMC), and mannoproteins, including their limitations and compatibility with protein stability. Throughout the discussion, Jim and Leigh emphasize correct sampling strategy, filtration level selection, and timing of tests to ensure results accurately represent the wine that will be bottled. Practical lab workflows, sample volume requirements, and real-world bottling considerations are covered to help winemakers reduce risk and avoid post-bottling stability issues. Leigh previously appeared on Inside Winemaking in May 2019 to discuss the founding and early development of her wine lab, MyEnologist, including its analytical services and role in supporting winemakers. This episode builds on that earlier conversation by applying lab-based analysis directly to cellar decision-making, with a focused, technical look at stability testing and intervention strategies used in modern winemaking.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he's now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
2026-01-26 | UPDATES #113 | “Treason” in the PLA? Xi's unprecedented purge — corruption, loyalty, and coup rumours. Today's story is not “just another corruption scandal” in China. This is the Chinese Communist Party reaching up into the absolute top of the People's Liberation Army — right into the room where war plans live — and yanking out two senior figures in one move. Top figures in fact. Beijing's official language is clipped. The implications are not. China's defence ministry says it has opened investigations into General Zhang Youxia — a vice chairman of the Central Military Commission, effectively the uniformed number two under Xi Jinping — and General Liu Zhenli, a CMC member and chief of the Joint Staff Department. The stated reason: “suspected serious violations of discipline and law.” (Reuters)----------SUPPORT THE CHANNEL:https://www.buymeacoffee.com/siliconcurtainhttps://www.patreon.com/siliconcurtain----------SOURCES: Xinhua: Defence ministry announcement (Jan 24, 2026). Xinhua / PLA Daily editorial summary (Jan 24, 2026). Reuters: Investigation details and context on PLA purges (Jan 24, 2026). Associated Press: Overview and recent purge timeline (Jan 24, 2026).Financial Times: Loyalty framing and “authority” angle (Jan 25, 2026). Washington Post: Scale of upheaval and command implications (Jan 25, 2026).Wall Street Journal: Reported additional allegations (unconfirmed by PRC statement) South China Morning Post: “Party purity” framing and political timing (Jan 25, 2026). Official explainer of the “CMC Chairperson Responsibility System” (SCIO, background).Reuters (background): Li Shangfu/Wei Fenghe expulsions (Jun 2024) and 2027 readiness reporting (Feb 2023). German Marshall Fund (background): Rocket Force shakeup (Aug 2023). Andrew Erickson (analysis aggregation; includes translated/linked primary text). Sinocism (analysis; discussion of messaging speed and implications). ----------SILICON CURTAIN LIVE EVENTS - FUNDRAISER CAMPAIGN Events in 2025 - Advocacy for a Ukrainian victory with Silicon Curtainhttps://buymeacoffee.com/siliconcurtain/extrasOur events of the first half of the year in Lviv, Kyiv and Odesa were a huge success. Now we need to maintain this momentum, and change the tide towards a Ukrainian victory. The Silicon Curtain Roadshow is an ambitious campaign to run a minimum of 12 events in 2025, and potentially many more. Any support you can provide for the fundraising campaign would be gratefully appreciated. https://buymeacoffee.com/siliconcurtain/extras----------
© 2020-2026 Ivy Podcast Discovery LLC
